BCPS - Oncology Supportive Care Exam Questions
With Correct Answers
Time frame for "acute" onset vomiting? - ANSWER 0-24 hours after chemo
administration
Time frame for "delayed" onset vomiting? - ANSWER >24 hours after chemo
administration
What "risk factor" actually decreases the incidence of emesis? - ANSWER History of
chronic alcoholism
What is the % cut-offs for ematogenicity of chemotherapy agents? - ANSWER Highly
emetic - >90% risk of emesis
Moderately emetic - >30 to 90% risk of emesis
Low emetogenicity - 10 to 30% risk of emesis
Minimally emetic - <10% risk of emesis
Recommended treatment regimen for CINV prevention for Cisplatin and other highly
emetogenic single agents - ANSWER DAY 1:
- NK1R antagonist PLUS
- 5-HT3 receptor antagonist PLUS
- Dexamethasone 12 mg IV/PO PLUS
- Olanazpine 10 mg
DAYS 2-4:
Dexamethasone and Olanzapine
, (if aprepitant used on Day 1, continue that on days 2 & 3. Otherwise NK1R antagonists
are just on Day 1)
Dexamethasone - 20 mg if used with rolipripitant or NO NK1R antagonist
Recommended treatment regimen for CINV prevention for Anthracycline combined with
cyclophosphamide in breast cancer - ANSWER Same as the Cisplatin regimen but no
dexamethasone on days 2-4 - not enough data to support it's use in this group.
DAY 1:
- NK1R antagonist PLUS
- 5-HT3 receptor antagonist PLUS
- Dexamethasone 12 mg IV/PO PLUS
- Olanazpine 10 mg
DAYS 2-4:
Olanzapine
Recommended treatment regimen for CINV prevention for Anthracycline combined with
cyclophosphamide in other cancers other than breast cancer? - ANSWER
Dexamethasone PLUS palonsetron
Recommended treatment regimen for CINV prevention for moderately-ematogenic,
carboplatin-based regimens - ANSWER ONCE doses of the following (ie no therapy past
day 1)
NK1R antagonist PLUS
5HT3 receptor antagonist PLUS
Dexamethasone
Recommended treatment regimen for CINV prevention for moderately-ematogenic,
With Correct Answers
Time frame for "acute" onset vomiting? - ANSWER 0-24 hours after chemo
administration
Time frame for "delayed" onset vomiting? - ANSWER >24 hours after chemo
administration
What "risk factor" actually decreases the incidence of emesis? - ANSWER History of
chronic alcoholism
What is the % cut-offs for ematogenicity of chemotherapy agents? - ANSWER Highly
emetic - >90% risk of emesis
Moderately emetic - >30 to 90% risk of emesis
Low emetogenicity - 10 to 30% risk of emesis
Minimally emetic - <10% risk of emesis
Recommended treatment regimen for CINV prevention for Cisplatin and other highly
emetogenic single agents - ANSWER DAY 1:
- NK1R antagonist PLUS
- 5-HT3 receptor antagonist PLUS
- Dexamethasone 12 mg IV/PO PLUS
- Olanazpine 10 mg
DAYS 2-4:
Dexamethasone and Olanzapine
, (if aprepitant used on Day 1, continue that on days 2 & 3. Otherwise NK1R antagonists
are just on Day 1)
Dexamethasone - 20 mg if used with rolipripitant or NO NK1R antagonist
Recommended treatment regimen for CINV prevention for Anthracycline combined with
cyclophosphamide in breast cancer - ANSWER Same as the Cisplatin regimen but no
dexamethasone on days 2-4 - not enough data to support it's use in this group.
DAY 1:
- NK1R antagonist PLUS
- 5-HT3 receptor antagonist PLUS
- Dexamethasone 12 mg IV/PO PLUS
- Olanazpine 10 mg
DAYS 2-4:
Olanzapine
Recommended treatment regimen for CINV prevention for Anthracycline combined with
cyclophosphamide in other cancers other than breast cancer? - ANSWER
Dexamethasone PLUS palonsetron
Recommended treatment regimen for CINV prevention for moderately-ematogenic,
carboplatin-based regimens - ANSWER ONCE doses of the following (ie no therapy past
day 1)
NK1R antagonist PLUS
5HT3 receptor antagonist PLUS
Dexamethasone
Recommended treatment regimen for CINV prevention for moderately-ematogenic,
